Coherus Oncology, Inc. (CHRS) Return on equity 2016–2025
Coherus Oncology, Inc. (CHRS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
275.4%FY2025 · since FY2016: -620.3% → 275.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 275.4% | — |
| FY2021 | -293.8% | -340.8 pp |
| FY2020 | 47.1% | -38.3 pp |
| FY2019 | 85.4% | — |
| FY2017 | -780.0% | -159.7 pp |
| FY2016 | -620.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →